7.15

1.42% 0.09

Arcturus Therapeutics Holdings Inc (ARCT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$7.06

Offen:

24-Stunden-Volumen:

38,847

Relative Volume:

0.08

Marktkapitalisierung:

$202.94M

Einnahmen:

$67.22M

Nettoeinkommen (Verlust:

$-65.78M

KGV:

-2.9958

EPS:

-2.3867

Netto-Cashflow:

$-79.02M

1W Leistung:

+6.55%

1M Leistung:

-13.94%

6M Leistung:

-67.70%

1J Leistung:

-40.08%

1-Tages-Spanne:

$6.98

$7.1699

1-Wochen-Bereich:

$6.54

$7.17

52-Wochen-Spanne:

$5.85

$24.17

Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile

Firmenname

Arcturus Therapeutics Holdings Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (623)

Telefon

(858) 900-2660

Adresse

10285 SCIENCE CENTER DRIVE, SAN DIEGO, CA

Mitarbeiter

111

Twitter

@ArcturusRx

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

ARCT's Discussions on Twitter

Compare ARCT vs VRTX, REGN, ALNY, ARGX, INSM

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ARCT Arcturus Therapeutics Holdings Inc	7.14	200.67M	67.22M	-65.78M	-79.02M	-2.3867
VRTX Vertex Pharmaceuticals Inc	452.38	115.58B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	754.66	79.23B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	329.83	43.59B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	687.12	43.26B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	147.06	31.97B	606.42M	-1.28B	-997.58M	-6.403

Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-18	Eingeleitet	B. Riley Securities	Buy
2026-01-23	Eingeleitet	Roth Capital	Buy
2025-10-24	Herabstufung	H.C. Wainwright	Buy → Neutral
2025-10-23	Herabstufung	Citigroup	Buy → Neutral
2025-10-22	Herabstufung	Guggenheim	Buy → Neutral
2025-09-04	Fortgesetzt	H.C. Wainwright	Buy
2025-05-28	Eingeleitet	Scotiabank	Sector Outperform
2025-01-28	Eingeleitet	BTIG Research	Buy
2024-08-12	Eingeleitet	Leerink Partners	Outperform
2023-12-13	Eingeleitet	Canaccord Genuity	Buy
2023-07-24	Eingeleitet	William Blair	Outperform
2023-05-11	Hochstufung	H.C. Wainwright	Neutral → Buy
2022-11-14	Fortgesetzt	Wells Fargo	Overweight
2022-11-10	Herabstufung	Robert W. Baird	Neutral → Underperform
2022-11-03	Hochstufung	Citigroup	Neutral → Buy
2022-11-02	Hochstufung	Barclays	Underweight → Equal Weight
2022-08-10	Herabstufung	Raymond James	Mkt Perform → Underperform
2022-07-19	Fortgesetzt	Cantor Fitzgerald	Overweight
2022-05-11	Hochstufung	Robert W. Baird	Underperform → Neutral
2022-04-21	Herabstufung	Citigroup	Buy → Neutral
2022-01-31	Hochstufung	Raymond James	Underperform → Mkt Perform
2021-08-12	Herabstufung	Raymond James	Mkt Perform → Underperform
2021-08-11	Herabstufung	Goldman	Neutral → Sell
2021-08-10	Herabstufung	Robert W. Baird	Neutral → Underperform
2021-07-02	Eingeleitet	Cantor Fitzgerald	Overweight
2021-06-25	Fortgesetzt	Goldman	Neutral
2021-06-21	Herabstufung	Barclays	Equal Weight → Underweight
2021-06-04	Fortgesetzt	Robert W. Baird	Neutral
2021-02-17	Herabstufung	B. Riley Securities	Neutral → Sell
2021-01-19	Herabstufung	B. Riley Securities	Buy → Neutral
2021-01-15	Herabstufung	B. Riley Securities	Buy → Neutral
2021-01-07	Eingeleitet	Wells Fargo	Overweight
2020-12-29	Herabstufung	Barclays	Overweight → Equal Weight
2020-12-29	Herabstufung	H.C. Wainwright	Buy → Neutral
2020-12-29	Herabstufung	Raymond James	Outperform → Mkt Perform
2020-12-29	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-12-23	Herabstufung	ROTH Capital	Buy → Sell
2020-12-08	Bestätigt	B. Riley Securities	Buy
2020-12-07	Bestätigt	B. Riley Securities	Buy
2020-10-26	Eingeleitet	Barclays	Overweight
2020-10-06	Eingeleitet	Citigroup	Buy
2020-08-26	Eingeleitet	Piper Sandler	Overweight
2020-07-30	Fortgesetzt	ROTH Capital	Buy
2020-07-16	Eingeleitet	Raymond James	Outperform
2020-07-13	Eingeleitet	B. Riley FBR	Buy
2020-06-09	Herabstufung	WBB Securities	Buy → Hold
2020-02-11	Eingeleitet	Robert W. Baird	Outperform
2020-02-07	Eingeleitet	Guggenheim	Buy
2020-02-06	Eingeleitet	Guggenheim	Buy
2019-04-05	Eingeleitet	H.C. Wainwright	Buy
2018-09-20	Hochstufung	WBB Securities	Buy → Strong Buy
2018-01-22	Eingeleitet	Chardan Capital Markets	Buy

Alle ansehen

Arcturus Therapeutics Holdings Inc Aktie (ARCT) Neueste Nachrichten

Mar 24, 2026

Understanding the Setup: (ARCT) and Scalable Risk - Stock Traders Daily

Mar 24, 2026

Mar 23, 2026

Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf - MarketBeat

Mar 23, 2026

Arcturus Therapeutics at the 38th Annual Roth Conference: Strategic Shift to Rare Diseases - Investing.com Canada

Mar 23, 2026

These Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley Fool

Mar 23, 2026

Arcturus Therapeutics stock plunges 50% after weak cystic fibrosis trial data - MSN

Mar 23, 2026

ARCT Stock Price, Quote & Chart | ARCTURUS THERAPEUTICS HOLDIN (NASDAQ:ARCT) - ChartMill

Mar 23, 2026

Mar 21, 2026

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 earnings call transcript - MSN

Mar 21, 2026

Mar 20, 2026

This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Benzinga

Mar 20, 2026

Arcturus Therapeutics (NASDAQ:ARCT) Stock Rating Upgraded by B. Riley Financial - MarketBeat

Mar 20, 2026

This BP Analyst Is No Longer Bearish; Here Are Top 4 Upgrades For Friday - Benzinga

Mar 20, 2026

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat

Mar 20, 2026

Mar 19, 2026

This Xponential Fitness Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Thursday - Benzinga

Mar 19, 2026

This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Mar 19, 2026

This Union Pacific Analyst Turns Bullish; Here Are Top 3 Upgrades For Wednesday - Benzinga

Mar 19, 2026

B Riley Securities initiates coverage of Arcturus Therapeutics Holdings (ARCT) with buy recommendation - MSN

Mar 19, 2026

Mar 18, 2026

Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics - Investing.com

Mar 18, 2026

Cathie Wood’s ARK sells Guardant Health stock, buys Arcturus Therapeutics By Investing.com - Investing.com Australia

Mar 18, 2026

Arcturus Therapeutics (NASDAQ:ARCT) Coverage Initiated at B. Riley Financial - MarketBeat

Mar 18, 2026

This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga

Mar 18, 2026

ARCT: B. Riley Securities Initiates Coverage with 'Buy' Rating | - GuruFocus

Mar 18, 2026

Mar 17, 2026

Arcturus Therapeutics stresses importance of phased clinical trials in drug development - Traders Union

Mar 17, 2026

Mar 16, 2026

Update Recap: How is Arcturus Therapeutics Holdings Inc managing supply chain issuesWeekly Stock Summary & Short-Term Swing Trade Alerts - baoquankhu1.vn

Mar 16, 2026

Can Arcturus Therapeutics Holdings Inc sustain its profitabilityMarket Sentiment Review & Reliable Entry Point Alerts - baoquankhu1.vn

Mar 16, 2026

Mar 13, 2026

The Technical Signals Behind (ARCT) That Institutions Follow - Stock Traders Daily

Mar 13, 2026

Mar 12, 2026

Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing - MarketBeat

Mar 12, 2026

Mar 09, 2026

Patients and scientists join forces for rare disease progress, Arcturus Therapeutics asserts - Traders Union

Mar 09, 2026

Mar 08, 2026

ARCT Should I Buy - Intellectia AI

Mar 08, 2026

Mar 07, 2026

Arcturus (ARCT) Q4 2025 Earnings Call Transcript - AOL.com

Mar 07, 2026

Mar 06, 2026

Stock Report: Can Arcturus Therapeutics Holdings Inc sustain its profitabilityJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Mar 06, 2026

Arcturus Therapeutics: Downgrading to "Hold" As CF Program Shifts Population Focus (ARCT) - Seeking Alpha

Mar 06, 2026

Arcturus Therapeutics to attend Leerink Partners 2026 Global Healthcare Conference - Traders Union

Mar 06, 2026

Citigroup Issues Pessimistic Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat

Mar 05, 2026

Arcturus Therapeutics to Attend Upcoming Investor Conference - PharmiWeb.com

Mar 05, 2026

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Q4 2025 Earnings Call Transcript - Insider Monkey

Mar 05, 2026

ARK Investment Management LLC Boosts Position in Arcturus Therapeutics Holdings Inc. $ARCT - MarketBeat

Mar 05, 2026

Piper Sandler Maintains Overweight on Arcturus Therapeutics (ARCT) March 2026 - Meyka

Mar 05, 2026

Mar 04, 2026

Gossamer Bio, Seralutinib Misses Tight Statistical Mark But Shows Heart In High-Risk Lung Disease Study - AOL.com

Mar 04, 2026

Arcturus Therapeutics Holdings ARCT Q4 Revenue Slide To US$7.2 Million Tests Growth Narrative - simplywall.st

Mar 04, 2026

Arcturus Therapeutics Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance

Mar 04, 2026

Citigroup Issues Positive Forecast for Arcturus Therapeutics (NASDAQ:ARCT) Stock Price - MarketBeat

Mar 04, 2026

Citigroup Raises Price Target for Arcturus Therapeutics (ARCT) t - GuruFocus

Mar 04, 2026

Piper Sandler Lowers Price Target for Arcturus Therapeutics (ARC - GuruFocus

Mar 04, 2026

New nasal vaccine protects lungs for months against viruses, bacteria, and allergens - AOL.com

Mar 04, 2026

Piper Sandler Cuts Arcturus Therapeutics (NASDAQ:ARCT) Price Target to $25.00 - MarketBeat

Mar 04, 2026

Arcturus Therapeutics reports financial results and pipeline progress - Traders Union

Mar 04, 2026